PROCEPT BioRobotics sets November 4 results date: what it means for PROCEPT BioRobotics stock
Published on 10/21/2026 at 00:18 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSRevenue and reporting schedule
- PROCEPT BioRobotics announced its third-quarter reporting event on October 12, 2026.
- Second-quarter revenue reached USD 94.50 million, up 19.30 percent year over year.
- Third-quarter results are scheduled for November 4, 2026, after market close.
PROCEPT BioRobotics (ISIN US74276L1052) announced on October 12, 2026 that it will report third-quarter 2026 results on November 4 after market close, according to GlobeNewswire. Management will host a conference call at 4:30 p.m. Eastern Time.
Revenue growth meets a wider loss
For the second quarter of 2026, revenue reached USD 94.50 million, up 19.30 percent from the prior-year quarter. Net loss widened to USD 26.86 million from USD 19.58 million, while diluted GAAP earnings per share came to a loss of USD 0.47, according to CEO.ca.
The same quarter delivered a 66.00 percent gross margin, compared with 65.00 percent a year earlier. The release attributed the improvement partly to pricing and a USD 2.90 million tariff refund, making the margin figure less clean as a measure of recurring progress.
What does November 4 mean?
The next report will test whether the company can extend its 19.30 percent revenue growth while controlling losses. PROCEPT BioRobotics had reiterated full-year 2026 revenue guidance of USD 390.00 million to USD 410.00 million in its second-quarter release.
Three dated corporate steps
On August 4, 2026, the company reported USD 94.50 million in second-quarter revenue, according to CEO.ca. On October 2, 2026, it expanded its board from nine to ten members by appointing Dr. Michael Mack as an independent director, according to the SEC.
On October 12, 2026, PROCEPT BioRobotics set November 4, 2026, as the date for its third-quarter report, according to GlobeNewswire.
Next date for investors
The next substantiated company date is November 4, 2026, when third-quarter results are due after market close and management is scheduled to begin its conference call at 4:30 p.m. Eastern Time.
Business remains centered on urology
PROCEPT BioRobotics develops, manufactures, and sells robotic systems for minimally invasive urologic surgery, with an initial focus on benign prostatic hyperplasia, according to the company's investor relations profile. Its market capitalization was USD 1.1 billion as of October 20, 2026, while the 52-week range was USD 16.66 to USD 38.11.
PROCEPT BioRobotics facts
- Company: PROCEPT BioRobotics Corporation
- ISIN: US74276L1052
- Ticker: PRCT
- Primary exchange: Nasdaq Global Market
- Market capitalization: USD 1.1 billion (as of October 20, 2026)
- 52-week range: USD 16.66-38.11 (as of October 20, 2026)
- Sector / Industry: Health care / medical devices
Market context: Market report S&P 500.
